Abstract: This invention provides a novel class of substituted macrocyclic metallic compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described.

Abstract: The present invention provides novel porphyrin derivatives represented by the general formula 1 and/or pharmaceutically acceptable derivatives thereof as NIR sensitizers for photodynamic therapeutic and diagnostic, biological and industrial applications. These porphyrin derivatives posses absorption (400-700 nm) and emission (600-750 nm) in the regions where biological chromophores do not absorb and hence are ideal candidates for application as NIR PDT agents and fluorescence sensors for medicinal applications in biology. The substituents like hydroxyl and glycolic units on these dyes render them amphiphilicity thereby improving their solubility in the aqueous media and cellular uptake and localization. These dyes show no toxicity in the dark and are highly selective towards tumor cells and stain nucleus very rapidly. Accordingly, these porphyrin derivatives are extremely useful as NIR PDT fluorescence sensors in photodynamic therapeutic and diagnostic, biological and industrial applications.

Abstract: A porphyrin coordination polymer nanostructure comprising a network of pyridyl porphyrin molecules and coordinating metal ions coordinatively bound through the pyridyl groups. In some embodiments, the porphyrins are metalloporphyrins. A variety of nanostructures are formed by the network polymer, including nanospheres, polygonal nanostructures, nanorods, and nanofibers, depending on a variety of factors including coordination metal ion, porphyrin type, metal of the metalloporphyrin, and degree of agitation during nanostructure formation. Reduction of coordinating metal ions may be used to form metal nanoparticles on the coordination polymer nanostructure.

Abstract: A long wavelength absorbing porphyrin/metalloporphyrin molecule is provided, made up of a porphyrin macrocycle and an anchor group for attachment to a substrate. A molecular linking element is interposed between the porphyrin macrocycle and the anchor group. The porphyrin/metalloporphyrin molecule also includes an (aminophenyl)amine group, either N,N-(4-aminophenyl)amine or N-phenyl-N-(4-aminophenyl)amine, where an amino moiety of the 4-aminophenyl group is derivatized by an element such as hydrogen, haloalkanes, aromatic hydrocarbons, halogenated aromatic hydrocarbons, heteroarenes, halogenated heteroarenes, or combinations of the above-mentioned elements.

Abstract: Light emitting devices are described which incorporate, as the light emitting element, a dendrimer of which the constituent dendrons include a conjugated dendritic structure comprising aryl and/or heteroaryl groups connected to each other via bonds between sp2 hybridised ring atoms of said aryl or heteroaryl groups.

Abstract: The invention provides method of use of a porphyrin compound as shown below in preparing a medicament for sonodynamic therapy, and a method of sonodynamic therapy using a porphyrin compound. Said therapy comprises administering a porphyrin compound to a patient and applying sonic wave to the patient, wherein each symbol has the meaning as defined in the description.

Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.

Abstract: The three-dimensional structure of the present invention is a three-dimensional structure formed on a base. This three-dimensional structure contains a plurality of porphyrins, a plurality of first metal ions, and a plurality of specific organic molecules. The porphyrin contains two or more functional groups. The first metal ion is a metal ion for linking the functional group of one porphyrin to the functional group of another porphyrin. The above specific organic molecule is an organic molecule that forms a coordinate bond with a metal ion contained in the two-dimensional structure and that has only one site to coordinate to the metal ion.

Abstract: Disclosed is a phthalocyanine compound characterized by being represented by the formula (1) below. This phthalocyanine compound has good affinity to titania, and is suitably used for an organic thin film of an organic solar cell and the like. [In the formula, M represents a hydrogen atom or a central metal; Z1 and Z2 independently represent a hydroxy group, an alkoxy group having 1 to 18 carbon atoms or a phenyl group; and Ar represents at least one aryl group selected from those represented by the following formulae (2) to (12). (In the formulae (2) to (12), R1 to R103 independently represent a hydrogen atom, a halogen atom, a hydroxy group, an amino group, a silanol group, a thiol group, a carboxyl group, a phosphoric acid group, a phosphate group, an ester group, a thioester group, an amide group, a nitro group, a monovalent hydrocarbon group, an organoxy group, an organoamino group, an organosilyl group, an organothio group, an acyl group or a sulfone group.

Abstract: A method of making chlorins comprises the steps of reacting (e.g. condensing) a dipyrrin western half intermediate with an eastern half intermediate to form a tetrahydrobilene, and then cyclizing the tetrahydrobilene to form a chlorin. Intermediates including tetrahydrobilenes useful in such reactions are also described.

Abstract: A method of producing a metal phthalocyanine compound, which contains: conducting a reaction between at least two compounds selected from among Compounds A to F of formula (I), and a metal compound, in a buffer solution of an organic base or an inorganic base and an acid, in the presence of a dehydrating agent: wherein R is a hydrogen atom or a substituent; l is an integer of 0 to 4; a plurality of Rs may be the same or different from each other when l is 2 to 4; and G is a group of atoms necessary for forming at least one of a 5- or 6-membered aromatic ring and a 5- or 6-membered hetero ring.

Abstract: Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described.

Abstract: A method of making a compound of Formula I? comprises reacting a compound of the formula DLCHO, with a compound of the formula to produce the compound of Formula I?. Methods of using the compounds are also described, particularly as intermediates for the synthesis of porphyrin rods, which porphyrin rods are in turn useful for (among other things) the production of molecular memory devices.

Abstract: The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing porphyrin compounds with halide, amine, or nitro groups and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT), and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing porphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.

Abstract: Meso-substituted porphyrins of general formula (I) suitable for the use as photosensitizing agents, in particular in photodynamic therapy, are herein described.

Abstract: This invention relates to the fields of pharmaceutics and medicine, and, in particular, relates to the production and use of pharmaceutical substances on the basis of mitochondria-addressed compounds. The invention discloses methods for synthesis, purification and storage of mitochondria-addressed antioxidants, making it possible to produce said substances in a form and quality meeting the demands made on active ingredients of medicinal preparations—the pharmaceutical substances. The invention also discloses methods for design and selection of new mitochondria-addressed antioxidants having specified properties.

Abstract: Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion.

Abstract: The application relates to a nanovesicle comprising a bilayer of at least 15 mol % porphyrin-phospholipid conjugate, wherein the conjugate comprises a porphyrin, porphyrin derivative or porphyrin analog covalently attached to the phospholipid side chain. The nanovesicle can be used for photothermal therapy, photoacoustic imaging, and fluorescence imaging. The application also discloses a method of preparing the said nanovesicle.

Abstract: A method of making a phosphono-substituted dipyrromethane comprises reacting an aldehyde or acetal having at least one phosphono group substituted thereon with pyrrole to produce a phosphono-substituted dipyrromethane; and wherein the phosphono is selected from the group consisting of dialkyl phosphono, diaryl phosphono, and dialkylaryl phosphono. Additional methods, intermediates and products are also described.

Abstract: The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.).

Abstract: The invention relates to an improved method of dynamic nuclear polarisation (DNP) of carboxylic acids and to compounds and compositions for use in the method.

Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.

Abstract: A method and a composition for photochemical cross linking of collagen by photoactive agent in-vivo are presented. The method includes a non-toxic photoactive formulation of the composition with collagen, which is administered to treatment area locally; followed by irradiation with suitable wavelength. In one of the embodiment liposomal formulated mTHPC is added to the collagen and is irradiated with a 652 nm laser, resulting in producing efficient collagen scaffolds with strengthen and stabilized microstructure, thus improving the physiochemical properties of the collagen scaffold. It improves the thermostability, mechanical property and swelling ratio of newly formed scaffold. Photochemical cross-linked collagens shows antimicrobial effect, when irradiated with suitable wavelength it disinfects the treatment site and curbs microbial growth.

Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.

Abstract: A highly dispersed, unsupported, electrocatalyst made of pyrolyzed porphyries and a method for synthesizing the same. The disclosed synthesis procedure allows for optimization of pore size and therefore transport properties. Compounds suitable for use include transition metal N4-chelates such as, but not necessarily limited to, N4-chelates containing different metal centers including Co, Fe, Mn, Ni, Ru, Cu, etc., and other N4-chelates such as porphyrin, phthalocyanies, and structures based on their pyro products.

Abstract: Compounds of formula (I) are disclosed. The tetrapyrole ring in formula (I) can be substituted with a metal cation (M); R1, R2, R3 and R4 separately represent a hydrogen atom, a C1-4 alkyl or alkyloxy radical, or a phenyl radical optionally substituted by vinyl, hydroxy, nitro, amino, bromo, chloro, fluoro, iodo, benzyloxy, or hydroxymethyl radicals; R5, R6, R7 and R8 separately represent a hydrogen atom or a C1-4 alkyl radical; Ra, Rb and Rc separately represent a hydrogen atom, a C1-4 alkyl or alkyloxy radical optionally substituted by a halogen, or a phenyl radical optionally substituted by vinyl, hydroxy, nitro, amino, bromo, chloro, fluoro, iodo, benzyloxy, or hydroxymethyl radicals, wherein at least one of Ra, Rb, and Rc is a phenyl radical. Compounds of formula (I) bound to a silica, a sol-gel material or a mesoporous silica are useful for selective trapping of carbon monoxide.

Abstract: The present invention relates to a composition for photon energy up-conversion, a system comprising said composition and to uses of said composition and said system.

Abstract: A process is described for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group, products useful as photosensitizing agents in photodynamic therapy.

Abstract: The present invention provides a porphyrin derivative having improved water solubility, desirably having both water solubility and lipophilicity. Specifically, the present invention provides a water-soluble porphyrin consisting of a tetraphenylporphyrin derivative represented by Formula (1): wherein m represents an integer of 1 to 30; n represents an integer of 2 to 4; R represents a hydrogen atom or an optionally substituted alkyl or aromatic group; Ph represents an optionally substituted phenyl group; and X? is a counterion and represents a halide ion, PF6?, or BF4?.

Abstract: This invention provides a novel class of substituted macrocyclic porphyrin compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described.

Abstract: The present invention relates to a photosensitizer-containing nanoparticle, comprising a photosensitizer covalently bonded throughout at least a part of said nanoparticle to the nanoparticle matrix material and incorporated therein in a quasi-aggregated state. The present invention further relates to methods for producing the invention nanoparticles, and to methods of killing cancer cells by PDT treatment using the said nanoparticles.

Abstract: Compositions comprising nitrosyl-cobinamide are provided. Also provided are methods for treating hypertension, which comprise administering therapeutically effective amounts of nitrosyl-cobinamide. Also provided are methods for producing nitrosyl-cobinamide.

Abstract: A method of producing a thin film comprising uniformly dispersed carbon nanotubes, the method comprising the steps of: adapting a molecular semiconductor to make it soluble; adapting the molecular semiconductor to facilitate the formation of a high degree of molecular order and frontier orbital overlap between adjacent molecules; adapting carbon nanotubes to make them soluble; combining the soluble carbon nanotubes and the soluble molecular semiconductor in a solvent to form a solution; producing the thin film from the solution.

Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.

Abstract: Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds ere also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.

Abstract: The present invention relates to a compound of formula (I) and compositions thereof, methods of their production as well as methods for treating bacterial infection.

Abstract: The present disclosure relates to multichromophoric assemblies comprising metalloporphyrin scaffolds. The present disclosure also relates, in part, to methods for generating electric-field-stabilized geminate polaron pairs comprising applying electric fields to the multichromophoric assemblies described herein, or alternatively, directly to the metalloporphyrins provided by the present disclosure. The present disclosure further relates, in part, to multichromophoric assemblies comprising metalloporphyrin scaffolds, which exhibit enhanced energy transfer properties.

Abstract: A method of making a porphyrin is carried out by: (a) condensing (i) a 1,9-bis(N,N-)dialkylaminomethyl)dipyrromethane of Formula II: with (ii) a dipyrromethane to produce a reaction product; then (b) oxidizing the reaction product; and then (c) optionally demetallating said reaction product to produce the porphyrin. The reaction is particularly useful for making substituted porphyrins with a wide range of substituents at the A and/or B (the 5 and/or 15) positions.

Abstract: The invention relates to topical pharmaceutical compositions comprising a phthalocyanine, wherein a diamagnetic metal ion moiety is either coordinated or covalently bound to the phthalocyanine core. The invention also relates to methods for destroying cancer tissue, precancerous cells, photo-aged cells, damaged cells, or otherwise pathologic cells, or activated cells, such as lymphocytes or other cells of the immune system, or activated or inflamed tissue cells comprising topically administering to the cancer tissue or surrounding tissue an effective amount of a phthalocyanine composition.

Abstract: A method of making chlorins comprises the steps of reacting (e.g. condensing) a dipyrrin western half intermediate with an eastern half intermediate to form a tetrahydrobilene, and then cyclizing the tetrahydrobilene to form a chlorin. Intermediates including tetrahydrobilenes useful in such reactions are also described.

Abstract: This patent covers a chemical process technology. This subject technology is about production of M-Hydrogen from water, using special catalyst in presence of sunlight. The hydrogen will be used for power generation, using hydrogen cells. Present hydrogen production technologies produce CO, CO2, NOX gases along with Hydrogen as byproducts. These gases are not environment friendly and injurious to human health. This patent chemical process is very different from presently available hydrogen production technologies. No similar harmful gases will be generated. Oxygen will be generated as a byproduct which will restore the environmental balance.

Abstract: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.

Abstract: The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 17<3>, 13<3> and 3<2> of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.

Abstract: A two-photon absorption material represented by the following General Formula (I): where R1 to R8 each represent hydrogen, halogen, a carboxyl group, a carboxylic acid ester group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted alkyl group; one to three of X1 to X4 each represent a substituted or unsubstituted amino group, a substituted or unsubstituted aminophenyl group, a substituted or unsubstituted dialkylaminophenyl group, a substituted or unsubstituted N,N-diphenyl-aminophenyl group, a substituted or unsubstituted indolyl group, or a substituted or unsubstituted azulenyl group, and the other represents or the others each represent hydrogen, halogen, a carboxyl group, a carboxylic acid ester group, a substituted or unsubstituted aryl group, a substituted or unsubstituted pyridinyl group, a substituted or unsubstituted alkyl group or a perhalogenoalkyl group; and M represents two hydrogen atoms or a divalent, trivalent or tetravalent metal atom which may have oxygen or

Abstract: The present invention provides compounds of the general Formula DI: along with methods of making such compounds, formulations containing the same, and methods of using the same (e.g., in photodynamic therapy, for the production of solar cells, etc.).

Abstract: This invention relates to methods, compositions, and apparatuses for producing macrocyclic compounds. First, one or more reactants are provided in a reaction medium, which are capable of forming the macrocyclic compound through a desired reaction pathway that includes at least cyclization, and which are further capable of forming undesired oligomers through a undesired reaction pathway that includes undesirable oligomerization. Oligomerization of such reactions in the reaction medium is modulated to reduce formation of undesired oligomers and/or to reduce separation of the undesired oligomers from the reaction medium, relative to a corresponding unmodulated oligomerization reaction, thereby maximizing yields of the macrocyclic compound. The macrocyclic compound so formed is then recovered from the reaction medium. Preferably, the macrocyclic compound spontaneously separates from the reaction medium via phase separation.

Abstract: An exemplary method of extracting chlorophyll is provided according to the embodiments of the present invention. The method includes the following steps: providing a plant leaf containing chlorophyll therein and smashing the plant leaf; extracting the chlorophyll from the smashed plant leaf by using an organic solvent, thereby achieving an extracted solution containing chlorophyll therein; filtering the extracted solution and concentrating the filtered solution; and collecting the concentrated solution containing chlorophyll. An exemplary method of measuring a consistency of the chlorophyll is also provided in the present invention.

Abstract: The invention is directed to an improved, reliably performable process for preparing triallyl isocyanurate (TAIC) by Cu2+-catalysed rearrangement of triallyl cyanurate (TAC) at at least 90° C. According to the invention, TAC and, if required, also a Cu2+ catalyst and solvent are fed continuously to a start reaction mixture after onset of the initially inhibited isomerization reaction, the isomerization is performed at from 90 to 160° C. and an amount of reaction mixture equivalent to the amount of reactant is drawn off continuously and sent to the workup. Preference is given to effecting the isomerization in TAIC as the reaction medium.

Abstract: This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy (PDT). The development of tumor imaging or improved photodynamic therapy agent(s) itself represent an important step, but a dual function agent (PET imaging and PDT) provides the potential for diagnostic body scan followed by targeted therapy.

Abstract: An acylated phthalocyanine of the formula: wherein, R1 and R2 are each selected from the group consisting of hydrogen, alkyl, alkoxy and acyl radicals of the formulae —COR and —CRHOH, whereby 1-4 of the 8 R1 and R2 radicals are selected from the group consisting of —COR and —CRHOH, and if R1 or R2 on a benzene ring is selected from —COR or —CRHOH, then the other respective R1 or R2 radical on the benzene ring is hydrogen, R is CH3(CH2)n— where n is 0-15, M is at least one of Mg, Zn, Cd, Cu, Ni, Co, Fe, Pt, Pd or Sn, alkyl is CnH2n+1 where n is 7-14, and alkoxy is OCnH2n+1 where n is 6-15.